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Proliferation and hypoxia affect the efficacy of radiothera-
py, but radiation by itself also affects the tumor microenvi-
ronment. The purpose of this study was to analyze temporal
and spatial changes in hypoxia, proliferation and apoptosis
after irradiation (20 Gy) in cells of a murine adenocarcinoma
tumor line (C38). The hypoxia marker pimonidazole was in-
jected 1 h before irradiation to label cells that were hypoxic
at the time of irradiation. The second hypoxia marker, CCI-
103F, and the proliferation marker BrdUrd were given at 4,
8 and 28 h after irradiation. Apoptosis was detected by means
of activated caspase 3 staining. After immunohistochemical
staining, the tumor sections were scanned and analyzed with
a semiautomatic image analysis system. The hypoxic fraction
decreased from 22% in unirradiated tumors to 8% at both 8
h and 28 h after treatment (P , 0.01). Radiation did not
significantly affect the fraction of perfused vessels, which was
95% in unirradiated tumors and 90% after treatment. At 8
h after irradiation, minimum values for the BrdUrd labeling
index (LI) and maximum levels of apoptosis were detected. At
28 h after treatment, the BrdUrd labeling and density of ap-
optotic cells had returned to pretreatment levels. At this time,
the cell density had decreased to 55% of the initial value and
a proportion of the cells that were hypoxic at the time of
irradiation (pimonidazole-stained) were proliferating (Brd-
Urd-labeled). These data indicate an increase in tumor oxy-
genation after irradiation. In addition, a decreased tumor cell
density without a significant change in tumor blood perfusion
(Hoechst labeling) was observed. Therefore, it is likely that in
this tumor model the decrease in tumor cell hypoxia was
caused by reduced oxygen consumption. q 2006 by Radiation Research
Society
INTRODUCTION
The tumor microenvironment is characterized by an ab-
normal and heterogeneously organized tumor vasculature
1 Address for correspondence: Department of Radiation Oncology,
POB 9101, Radboud University Nijmegen Medical Centre, 6500 HB Nij-
megen, The Netherlands; e-mail: A.Ljungkvist@rther.umcn.nl.
(1–4). There is often an imbalance between tumor cell pro-
liferation and cell death, resulting in uncontrolled tumor
growth. Tumor cell proliferation is generally decreasing at
increasing distances from blood vessels. Frequently tumor
cells outgrow the vascular supply, resulting in tumor cell
hypoxia, which is often found at greater distances from
blood vessels or surrounding regions of tumor necrosis (4–
8). In addition, fluctuations in tumor blood flow result in
different gradients of oxygen and nutrients (9, 10). Con-
sequently, in many tumors, the hypoxic cell population is
heterogeneous with respect to the level and duration of hyp-
oxia. Hypoxic tumor cells can promote malignant progres-
sion by secretion of growth factors that stimulate angio-
genesis, cell proliferation and metastasis (11, 12). The
unique features of the tumor microenvironment such as pro-
liferation, hypoxia and apoptosis can be exploited as spe-
cific targets for anti-cancer treatments, and the relevance of
these parameters for radiotherapy is well recognized.
Loss of local control with increasing overall treatment
time has demonstrated the importance of tumor cell prolif-
eration in patients with head and neck and cervical cancer
who are treated with radiotherapy (13–17). Continuous hy-
perfractionated accelerated radiotherapy (CHART) has
shown that by reducing the overall treatment time, a sig-
nificant gain can be obtained for non-small cell lung cancer
(18). Also, in head and neck cancer, improved local control
with accelerated schedules has been demonstrated in ran-
domized trials (19, 20). For head and neck cancer, histo-
logical proliferation patterns have shown a better predictive
power for treatment outcome than either labeling index or
potential doubling time alone (21). This indicates that si-
multaneous assessment of different parameters of the tumor
microenvironment may improve the development of pre-
dictive assays.
Tumor cell hypoxia is predictive for local control and
survival after surgery or radiotherapy for carcinomas of the
head and neck and uterine cervix (22–25). It is well known
that radiotherapy is less effective under hypoxic conditions
than under well-oxygenated conditions. Moreover, radiation
by itself also affects tumor hypoxia and cell kinetics. Reox-
ygenation has been reported to occur within 24–72 h after
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FIG. 1. Treatment schedule and experimental design. See the text for
details.
treatment, and it may affect the efficacy of the subsequent
fraction in a conventional fractionation schedule (26–29).
Indirect evidence for a rapid increase in the oxygen tension
after irradiation has been obtained with radiobiological as-
says for several tumor lines (26, 30). Measurements of pO2
have shown that early reoxygenation occurs within 3–6 h
after irradiation. It was hypothesized that this is caused by
both decreased oxygen consumption and increased oxygen
delivery (28, 31).
Dynamic processes in the tumor microenvironment can
be visualized with immunohistochemical staining of endog-
enous and exogenous markers, which can be analyzed in
relation to tumor vasculature with microregional imaging
techniques (4, 7, 32–34). Several exogenous markers of
hypoxia such as pimonidazole, EF5 and CCI-103F are
available (7, 8, 32, 35). With consecutive injection of two
hypoxic cell markers, pimonidazole and CCI-103F, treat-
ment-induced changes in hypoxia can be measured, allow-
ing each tumor to serve as its own control (36–38). For
detection of proliferation, the exogenous markers bromo-
deoxyuridine (BrdUrd) and iododeoxyuridine (IdUrd) can
be used (4, 39, 40).
In this study, spatial and temporal changes in hypoxia,
proliferation and apoptosis were studied after a single ra-
diation dose of 20 Gy in the murine tumor line C38. Se-
quential injection of pimonidazole and CCI-103F was used
to detect changes in hypoxia during the first 28 h after
irradiation. Changes in tumor cell proliferation (BrdUrd)
and apoptosis (activated caspase 3) were analyzed in rela-
tion to the cells that were hypoxic at the time of irradiation.
MATERIALS AND METHODS
Tumor Model and Markers of Hypoxia, Perfusion and Proliferation
As the tumor model, cells of the murine colon adenocarcinoma line
C38 grown in C57BL/6 mice were used (41). Small tumor pieces were
transplanted subcutaneously into the right hind leg of anesthetized mice.
Experiments started when the tumors reached a mean diameter of 6–8
mm (n 5 26). All mice were kept at the Central Animal Laboratory in
accordance with institutional guidelines. Approval of the local ethical
committee for animal use was obtained for all experiments.
For detection of changes in hypoxia, the 2-nitroimidazoles pimonida-
zole hydrochloride (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole
hydrochloride) (Chemicon International, Inc., Temecula, CA) and CCI-
103F [1-(2-hydroxy-3-hexafluoroisopropoxy-propyl)-2-nitroimidazole; a
gift from J. A. Raleigh, Department of Radiation Oncology, University
of North Carolina, Chapel Hill, NC] (42) were used at a dose of 80 mg/
kg. These bioreductive compounds differ only in the immunologically
detectable side chain. Double staining of consecutively injected markers
in nontreated tumors results in a good spatial match, although pimoni-
dazole generally covers a slightly larger area than CCI-103F (36, 37).
Pimonidazole was dissolved in saline and injected intraperitoneally (i.p.)
in a volume of 0.5 ml. A mixture of CCI-103F and the proliferation
marker BrdUrd (50 mg/kg) dissolved in 10% DMSO and 90% peanut oil
was given i.p. in a volume of 0.5 ml. As a perfusion marker, Hoechst
33342 (Sigma) was given intravenously at a dose of 15 mg/kg in 0.1 ml
saline.
Irradiation and Experimental Setup
The irradiation setup has been described previously (27). The animals
were irradiated under anesthesia with an irradiation field of 3 3 2 cm on
the tumor-bearing hind leg. A total dose of 20 Gy was given with a 16
MV photon beam at a dose rate of 2 Gy per minute.
Pimonidazole, which is very stable once it is reduced and bound in
hypoxic cells (37, 43), was given 1 h before irradiation followed by the
mixture of CCI-103F and BrdUrd at 4, 8 and 28 h after irradiation (Fig.
1). At 2.5 h after injection of CCI-103F, the perfusion marker Hoechst
33342 was injected. One minute later, the animals were killed humanely
and the tumors were snap-frozen in liquid nitrogen. For each time, a
control group kept under ambient conditions was injected with markers
as described above. Four to five animals were used in each group.
Immunohistochemistry
Frozen sections (5 mm) were fixed in acetone (48C), and the Hoechst
33342 signal was recorded on air-dried tissue sections. After rehydration,
three consecutive tumor sections were triple-stained for pimonidazole and
vasculature in combination with CCI-103F, BrdUrd or activated caspase 3.
Pimonidazole was detected with a polyclonal rabbit anti-pimonidazole
(a gift from J. A. Raleigh) (44) and donkey anti-rabbit F(ab9)2Alexa488
(Molecular Probes, Eugene, OR). For staining of the blood vessels, un-
diluted 9F1 supernatant [rat monoclonal to mouse endothelium, (Depart-
ment of Pathology, Radboud University Nijmegen Medical Centre, Nij-
megen, The Netherlands)] and chicken anti-rat ALEXA647 (Molecular
Probes) were used. CCI-103F was detected with a polyclonal rabbit anti-
CCI-103F antibody (a gift from J. A. Raleigh) (45), followed with Biotin-
SP-conjugated donkey anti-rabbit F(ab9)2 and Cy3-conjugated mouse
anti-biotin antibody (Jackson Immuno Research Laboratories, West
Grove, PA). For detection of apoptosis, rabbit anti-active caspase 3 (R&D
Systems Inc. Minneapolis, MN) was used, followed by donkey anti-rabbit
Fabpbiotin (Jackson Immuno Research). Subsequently, streptavidin-Cy3
and goat anti-rabbit FabpCy3 (Jackson Immuno Research) were used. For
BrdUrd staining, the tumor sections were first denatured in 0.2N HCl for
10 min followed by neutralization for 10 min in 0.1 M borax. BrdUrd
was visualized with sheep anti-BrdU IgG (Abcam Ltd., Cambridge, UK)
and donkey anti-sheep F(ab9)2-Cy3 (Jackson Immuno Research). For
analysis of the BrdUrd labeling index, all nuclei were stained with pro-
pidium iodide (Molecular Probes).
Image Acquisition, Processing and Analysis
The tumor sections were mounted with Fluorostab (ICN Pharmaceu-
ticals, Inc.) and analyzed quantitatively with a semi-automatic image re-
cording system as described previously (46). Using different filter sets,
multiple scans at 1003 magnification yielded composite images with the
two hypoxia markers. At 2003 magnification, composite images with
pimonidazole and either proliferation or apoptosis were obtained. The
grayscale images were thresholded into binary images (37, 47), which
were used for quantitative analysis of spatial relationships between pro-
liferation, hypoxia and apoptosis. A consecutive H&E-stained tumor sec-
tion was used to define the tumor area excluding non-tumor tissue, ne-
crosis and staining artifacts.
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The hypoxic fractions of pimonidazole (HF-pimo) and CCI-103F (HF-
CCI) were defined as the areas positive for pimonidazole or CCI-103F
divided by the total tumor area. The fraction of perfused vessels (PF)
was defined as the number of pixels positive for both vasculature (9F1)
and perfusion (Hoechst 33342) divided by the total number of vascular
pixels. The relative cell density was defined as the number of pixels
positive for propidium iodide divided by the total tumor area. The relative
cell density of proliferating cells was calculated as the number of BrdUrd-
positive pixels divided by the total tumor area. The labeling index (LI)
was calculated as the BrdUrd-labeled pixels divided by the propidium
iodide (all nuclei)-labeled pixels. The densities of apoptotic cells were
defined as the number of objects positive for activated caspase 3 divided
by (1) the tumor area, (2) the pimonidazole positive area, and (3) the
non-pimonidazole-stained tumor area, respectively. The tumors in all con-
trol groups were pooled for analysis of perfusion, proliferation and apo-
ptosis since labeling of these markers occurred at a constant interval
relative to tumor harvest.
Statistics
The statistical analyses were done on a Macintosh computer using
GraphPad Prism version 4 (GraphPad Software, San Diego, CA). For all
parameters, a comparison of control and irradiated tumors was made with
ANOVA followed by the Tukey test. A P value below or equal to 0.05
was considered statistically significant.
RESULTS
Dynamics of Hypoxia in Unirradiated Compared to
Irradiated Tumors
The pseudo-colored binary images in Fig. 2 show the
spatial distribution of the first hypoxia marker pimonidazole
(green) and the second hypoxia marker CCI-103F (red) rel-
ative to the tumor vasculature (white). The yellow color
reflects overlap of the two hypoxia markers. The time be-
tween injection of CCI-103F and harvest was always 2.5
h, but the interval between irradiation and CCI-103F injec-
tion varied (4, 8 and 28 h). Pimonidazole was always given
1 h before irradiation. Thus CCI-103F reflects the hypoxic
status at various times after irradiation, whereas pimoni-
dazole identifies cells that were hypoxic at the time of ir-
radiation.
There was a good spatial co-localization of the two hyp-
oxia markers in the 4-h group in unirradiated tumors and
the fraction of CCI-103F stained cells was similar in all
untreated tumors (Fig. 2). With increasing intervals be-
tween the hypoxia marker injections, the pimonidazole-
stained cells (green) started to disappear and pimonidazole-
labeled cell fragments appeared in the necrotic regions.
Bioreductive hypoxia markers can be reduced and bound
only in viable cells (intact and metabolically active). There-
fore, elimination of pimonidazole-positive cells reflects
clearance of cells that have died in the interval between
pimonidazole injection and tumor harvest, reflecting the
turnover of initially hypoxic cells (37). This was illustrated
as a reduction of the tumor areas showing co-localization
of pimonidazole and CCI-103F (yellow). The first sign of
elimination of pimonidazole-labeled cells was found at 8 h
and was more pronounced at 28 h. At the latter time, a
‘‘red margin’’ of one to two cell layers labeled only with
CCI-103F appeared at the vessel side of the hypoxic areas.
Those cells were not yet hypoxic at the time of the first
hypoxia marker injection but had migrated away from the
blood vessels within this period. The remains of dead cells
appeared as cell debris labeled with pimonidazole in the
necrotic tumor areas. Figure 2 shows the tumor sections
after quantification and exclusion of cell debris from the
images. In the untreated tumors, the hypoxic fraction based
on pimonidazole staining decreased from 30% in the 4-h
group to 18% in the 28-h group (P , 0.01), while the mean
hypoxic fraction based on CCI-103F staining did not differ
significantly in any of the control tumors (Fig. 3).
The first hypoxia marker, pimonidazole, was given 1 h
before irradiation. Since the half-life of pimonidazole in
murine blood plasma is around 30 min (48), the majority
of pimonidazole-labeled cells were hypoxic during irradi-
ation. Due to intertumor heterogeneities between untreated
and irradiated tumors in the 4-h group, there was a small
variation in the mean hypoxic fractions of pimonidazole.
Nevertheless, the spatial distribution and the relative dif-
ferences in hypoxic fraction as measured by the first and
second hypoxia marker were identical in untreated and ir-
radiated tumors (Figs. 2 and 3). At 8 and 28 h after irra-
diation, there was a clear decrease of the second hypoxia
marker CCI-103F (red) compared to the first marker pi-
monidazole (green). This is illustrated in Fig. 2 as a de-
crease in co-localization of both hypoxia markers (yellow)
resulting in areas stained with only the first hypoxia marker,
pimonidazole (green). The mean hypoxic fractions of CCI-
103F decreased from 22% in unirradiated tumors to 8% at
8 h after irradiation (P , 0.001) and to 8% at 28 h after
irradiation (P , 0.001) (Fig. 3). Thus the hypoxic fraction
decreased by a factor of three after irradiation, which is in
accordance with treatments with 10 Gy in cells of the
SCVII (28, 49) and SCCNij3 (27) tumor lines. In contrast
to untreated tumors, in the irradiated animals, there was no
significant change in hypoxic fractions of pimonidazole for
the various times (Fig. 3). The fraction of perfused blood
vessels was 95% (75–99) in unirradiated tumors and 90%
(71–96) after irradiation. Thus irradiation resulted in an in-
crease in the oxygenation status (decreased hypoxic frac-
tions of CCI-103F) and a decreased turnover rate of initially
hypoxic cells (unchanged hypoxic fractions of pimonida-
zole), while the fraction of functional blood vessels was
unaffected.
Radiation-Induced Changes in Proliferation
Radiation-induced changes in tumor cell proliferation
were analyzed by means of BrdUrd administration at dif-
ferent times after treatment. The left panels of Fig. 4 show
the spatial distribution of BrdUrd (red) in relation to the
oxygenation status at the time of irradiation (pimonidazole,
green) and vasculature (white). At 4 and 8 h after treatment,
the BrdUrd labeling could not be analyzed quantitatively
due to extensive cell death (H&E-stained sections, Fig. 4).
329HYPOXIA, PROLIFERATION AND APOPTOSIS AFTER IRRADIATION
FIG. 2. Composite binary images of sections of the murine tumor C38 (colon adenocarcinoma). Vasculature (9F1, white), perfusion marker (Hoechst
33342, blue), first hypoxia marker (pimonidazole, green), and the second hypoxia marker (CCI-103F, red); overlap of the two hypoxia markers is yellow.
The left panel shows control tumors and the right shows tumors treated with a single dose of X rays (20 Gy). The intervals between irradiation and
harvest are indicated in the images. Pimonidazole shows the initially hypoxic cell population and CCI-103F shows the cell population that was hypoxic
at time of harvest. Original magnification 1003, scale bar 5 1 mm. Areas of necrosis were excluded from the images (see Materials and Methods).
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FIG. 3. Hypoxic fractions for the first hypoxia marker pimonidazole
(squares) and the second hypoxia marker CCI-103F (circles) in (panel A)
untreated tumors (open symbols) and (panel B) irradiated tumors (solid
symbols). Error bars are means 6 SEM.
This was caused by the relatively high radiation dose and
resulted in nonspecific staining of BrdUrd. Microscopic ex-
amination of viable tumor areas indicated an almost com-
plete absence of proliferating tumor cells at these times. At
28 h after irradiation, the clearance of dead cells was almost
complete (H&E-stained sections, Fig. 4), and a rapid re-
covery of tumor cell proliferation was observed (Fig. 4, left
panel). The BrdUrd labeling index (number of BrdUrd-la-
beled cells/total number of cells) was 16% (range 7–28) in
the control tumors and 17% (range 10–27) at 28 h after
irradiation. However, at this time, the density of BrdUrd-
labeled cells had decreased to 48% of the pretreatment val-
ue and the total cell density had decreased to 55%. Thus,
at 28 h after irradiation, the cell density had been reduced
due to cell death, but the proportion of BrdUrd-labeled cells
relative to the total number of viable cells had recovered
to pretreatment levels (Fig. 4).
In unirradiated tumors, BrdUrd-labeled cells were found
mainly in the proximity of the vessels. In contrast, at 28 h
after irradiation, the distribution of proliferating cells was
more random and was independent of distance from the
vasculature. Furthermore, cells labeled with both the first
hypoxia marker, pimonidazole (green), and the proliferation
marker BrdUrd (red) were frequently observed at 28 h after
irradiation, appearing as yellow dots within the pimonida-
zole-labeled area. A comparison with the double hypoxia
marker staining showed that in general these cells were not
labeled with the second hypoxia marker. Thus, upon im-
provement of the oxygenation status, a proportion of the
initially hypoxic cells were labeled with BrdUrd.
Radiation-Induced Apoptosis
The right panels in Fig. 4 show apoptotic cells (activated
caspase 3, red) in relation to the first hypoxia marker (pi-
monidazole, green) and vasculature (white). In untreated
tumors, approximately 95% of all apoptotic cells were lo-
cated in pimonidazole-labeled areas and were situated near
necrotic areas.
Radiation-induced cell death in tumors at 4 and 8 h after
irradiation is illustrated in the H&E-stained sections shown
in Fig. 4. A substantial proportion of the irradiated cells
had shrunk and contained condensed nuclei, which are mor-
phological hallmarks of apoptosis. There was a significant
threefold increase in the density of apoptotic cells (caspase
3, Fig. 4, right panels) at both 4 h (P , 0.001) and 8 h (P
, 0.01) after irradiation (Fig. 5). The increase in the den-
sity of apoptotic cells was about 10-fold in tumor areas that
were not hypoxic at the time of irradiation compared to a
threefold increase in initially hypoxic regions (labeled with
both pimonidazole and caspase 3). At 28 h after irradiation,
the majority of the apoptotic cells had been cleared from
the tissue and the density of apoptotic cells had returned to
pretreatment levels in both the hypoxic and nonhypoxic cell
populations. However, at this time, the cell density had de-
creased by about 50%. Thus the relative number of apo-
ptotic cells was still above control levels. In the control
groups, an increase in the density of apoptotic cells was
noted at 28 h in pimonidazole-stained areas (Fig. 5B). This
can be explained by an accumulation of cells that had been
hypoxic at the time of irradiation and were driven into ap-
optosis during the 28 h after pimonidazole injection. Cell
debris labeled with pimonidazole was found in the necrotic
areas and was excluded from the quantitative analysis. In
Figs. 2 and 4, which show the resulting images after pro-
cessing, these areas appear as black holes after the masking
procedure.
DISCUSSION
Kinetics of Hypoxic Cells
In this study, both spatial and temporal changes in hyp-
oxia were visualized in tumors after consecutive injection
of two different bioreductive hypoxic cell markers. The
hypoxia markers pimonidazole and CCI-103F are very sim-
ilar and differ only in the immuno-recognizable side chain.
Therefore, these markers label cells with similar oxygena-
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FIG. 4. The left panel shows details of composite binary images of vasculature (9F1, white), the first hypoxia marker (pimonidazole, green) given
before and the proliferation marker (BrdUrd, red) given after irradiation. Overlap of proliferation and hypoxia is yellow. The middle panel shows H&E-
stained sections of the same tumors. The right panel shows composite binary images of vasculature (9F1, white), the first hypoxia marker (pimonidazole,
green), and apoptosis (activated caspase 3, red). Overlap of apoptosis and hypoxia is yellow. The top row shows untreated tumors with the same
injection intervals of the markers as in tumors harvested 4 h after irradiation. The subsequent rows show tumors at 4, 8 and 28 h after a single dose
of X rays (20 Gy). Original magnification 2003. Areas of necrosis were excluded from the images (see the Materials and Methods).
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FIG. 5. Panel A shows overall density of apoptotic cells (number of
apoptotic cells/mm2) as function of time in irradiated tumors (solid
squares) and control tumors (open squares). Panels B and C show the
densities of apoptotic cells in the initially hypoxic and initially non-hyp-
oxic tumor areas, respectively.
tion status and can be visualized by immunohistochemical
staining in the same tumor section without cross reactivity
(36, 37).
In unirradiated tumors, CCI-103F was administered at
fixed intervals before tumor harvest and pimonidazole was
given at variable times before analysis. Without treatment,
the decrease in pimonidazole at 8 and 28 h relative to the
4-h point was caused by clearance of cells that were hyp-
oxic at the time of its injection (37). This is illustrated by
the appearance of one or two cell layers labeled with only
the second hypoxia marker (Fig. 2, red) at the vessel side
of cells labeled with both hypoxia markers (yellow). The
hypoxic cell turnover rate was heterogeneous throughout
tumor sections, and regions with a slower hypoxic cell turn-
over were present in the tumor section shown in Fig. 2
(green only, unirradiated tumor section at 28 h). Cell debris
labeled with pimonidazole that appeared in the necrotic re-
gions was excluded from analysis and in the images shown
in Fig. 2. In previous studies, it was shown that large dif-
ferences in the life span and turnover rate of hypoxic cells
exist among different tumor lines (37, 43, 50). It is also
well known that radiation preferentially kills well-oxygen-
ated cells, with a subsequent reoxygenation of the surviving
cells. Therefore, it is likely that tumor-dependent kinetics
of hypoxic cells affects the response to radiation.
One of the aims of this study was to analyze the kinetics
of radiation-induced changes in hypoxic cells. In unirradi-
ated tumors, the initially hypoxic cells were almost com-
pletely eliminated 28 h after injection. In contrast, after
irradiation the hypoxic fraction based on pimonidazole
staining did not decrease. If the initially hypoxic cell pop-
ulation was very radioresistant, an increase in the hypoxic
fraction of pimonidazole-labeled cells compared to the total
number of surviving tumor cells could be expected. How-
ever, at 28 h after irradiation, the cell density within the
tumor surface had decreased, but the time until tumor har-
vest was too short to detect significant tumor shrinkage.
Moreover, the hypoxic fraction was determined as the area
of pimonidazole-labeled cells (initially hypoxic) divided by
the total tumor area, irrespective of the number of cells.
Therefore, a constant hypoxic fraction of pimonidazole-la-
beled cells before and after irradiation does not exclude an
absolute increase in pimonidazole-labeled cells in irradiated
tumors relative to the total number of surviving tumor cells.
After irradiation, the initially hypoxic (pimonidazole-la-
beled) cells were not labeled with the second hypoxia mark-
er, CCI-103F, indicating a radiation-induced increase in the
oxygenation of these cells. To exclude the possibility that
irradiation had resulted in deficient intracellular reductases,
a separate set of tumors were clamped at 28 h after irra-
diation. The intracellular reduction and binding are similar
for all 2-nitroimidazoles (51–54), as are the spatial distri-
butions of pimonidazole and CCI-103F (36, 55). Therefore,
it was assumed that if pimonidazole could be reduced after
irradiation, this would be similar for CCI-103F. Due to its
more rapid accumulation and binding, pimonidazole was
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chosen as hypoxia marker for the clamping experiments. In
the clamped and irradiated tumors, an intense pimonidazole
labeling indicated that at 28 h after irradiation the tumor
cells were well able to reduce 2-nitroimidazoles such as
pimonidazole and CCI-103F.
The hypoxic fraction measured with the second hypoxia
marker (CCI-103F) had decreased significantly at 8 h after
irradiation and remained low for at least the subsequent 20
h. Comparison with the first hypoxia marker, pimonidazole,
showed that the improvement of the oxygenation status was
evenly distributed throughout the tumor section. In unper-
turbed C38 tumors, the hypoxic cell turnover rate is more
rapid than the metabolism and clearance of reduced and
bound pimonidazole (37). Moreover, a larger fraction of
initially hypoxic cells was present in the tumor tissue 24 h
after irradiation than at the same time in nonirradiated tu-
mors. Therefore, it is unlikely that the present results were
influenced by the rate of metabolism of reduced and bound
drug. However, if the life spans of the hypoxic tumor cells
exceed the time needed for metabolism and clearance of
reduced and bound marker from the cells, the stability of
the bound marker could affect the interpretation of data.
Binding of misonidazole and other 2-nitroimidazoles
show a steep increase below 10 mmHg with a Km around
1–2 mmHg, which is close to the Km of radioresistance,
which usually falls between 2 and 4 mmHg (44, 48, 56–
58). In addition, it has been shown that irradiation results
in an increased oxygen tension (28, 49, 59, 60). Therefore,
it can be concluded that the decrease in hypoxia marker
staining after irradiation corresponds to an actual increase
in oxygen tension (61).
Although neither erythrocyte delivery nor oxygen deliv-
ery was actually measured, it is likely that the majority of
the Hoechst 33342-positive vessels were also subject to
erythrocyte flow. However, plasma flow, defined as the
presence of perfusion marker without accompanying red
blood cell flux, has been reported in up to 9% of (predom-
inantly small) vessels in the R3230AC mammary carcino-
ma (9). Therefore, the data in the current study suggest that
in the C38 line, radiation did not affect tumor blood flow,
but an effect on oxygen delivery could not be excluded.
Thus irradiation resulted in a decreased elimination rate of
initially hypoxic cells and an increased oxygen tension.
Dynamics of Radiation-Induced Changes in Proliferation
and Apoptosis
At 4 and 8 h after irradiation, there was a threefold over-
all increase in apoptosis, which was as much as tenfold in
initially non-hypoxic areas. This is in agreement with ra-
diation-induced programmed cell death of relatively nor-
mally oxygenated and radiosensitive cells. The clearance of
dead cells after irradiation seemed to be rapid since the
density of apoptotic cells had returned to the level of that
in unirradiated tumors within 28 h. However, the total cell
density had decreased by almost 50%; therefore, the pro-
portion of apoptotic cells relative to the total number of
cells was still elevated compared to untreated tumors. This
was in accordance with the qualitative analysis (Fig. 4) in-
dicating that cell death after irradiation in this tumor line
was mainly due to apoptosis. However, in our opinion, the
presence of apoptotic lymphocytes or an effect of radiation
on the turnover rate of apoptotic cells is unlikely but cannot
be completely excluded.
The decrease in proliferation at 4 and 8 h after irradiation
was clearly present upon visual assessment. However, there
was an increased level of nonspecific staining in necrotic/
apoptotic cells induced by the relatively high radiation dose
(H&E-stained sections, Fig. 4). Therefore, it was not pos-
sible to distinguish viable proliferating cells in the binary
images. Although the tumor sections at 8 h after irradiation
appeared to be dominated by apoptotic cells, visual exam-
ination at higher magnification showed that each apoptotic
cell was surrounded by several viable and intact cells. At
28 h after irradiation, quantitative analysis showed that the
BrdUrd labeling index had returned to pretreatment levels,
indicating that these cells either were proliferating (S phase)
or were subject to DNA repair. It is well known that a large
radiation dose results in a G2 block ranging from 0.8–3.0
h/Gy (62, 63). Flow cytometry has shown that the duration
of S phase is about 8 h in the C38 tumor (unpublished
results). The maximal quantity of BrdUrd incorporated in
repairing cells is profoundly less than the amount incor-
porated during replicative DNA synthesis. In the current
study, the brightness of the BrdUrd signal intensity at 28 h
after irradiation was similar to that in control cells. Con-
sidering the general length of G2/M blocks and the duration
of S phase, it is likely that the majority of the BrdUrd-
labeled cells observed at this time were in the first repli-
cative S phase after irradiation. Many of the BrdUrd-la-
beled tumor cells may be doomed to die after one or two
cell divisions. In addition, it has been shown that induction
of apoptosis can occur in parallel with replicative DNA
synthesis (64), resulting in BrdUrd labeling but not yet de-
tectable features of apoptotic cells. Since we studied only
the early kinetics after irradiation, effects due to apoptosis
or doomed cells cannot be ruled out. In this study, the
BrdUrd labeling index had returned to pretreatment levels
at 28 h after irradiation, but the absolute number of labeled
cells was still lower than in unirradiated tumors due to the
decrease in cell density (H&E staining, Fig. 4).
In contrast to untreated tumors, the distribution of pro-
liferating cells was more random and was independent of
the vasculature in irradiated tumors. In addition, the relative
number of cells labeled with both BrdUrd and pimonida-
zole (Fig. 4, yellow dots) was higher than in control tumors.
There could be a potential problem with delivery of BrdUrd
in tumor cells, which could result in an underestimation of
the proliferation rate. It has been argued that the dose gen-
erally used for in vivo labeling is too small to give maximal
labeling at larger distances from the vasculature (65). How-
ever, the presence of different patterns of BrdUrd labeling
334 LJUNGKVIST ET AL.
among tumors argues against this. A histological pattern
with a random distribution of proliferation was described
with S-phase cells also present at larger distances from the
vasculature (66). Also, the distance at which BrdUrd la-
beling still was present (200 mm from the vasculature) (4)
indicates that the dose used is sufficient to label prolifer-
ating cells further away from the vasculature. However,
there might be a risk of underestimation of the BrdUrd
labeling around nonperfused (Hoechst-negative) blood ves-
sels (67). In the current study, the proportion of functional
(perfused) blood vessels was similar in both the controls
and the irradiated tumors. Therefore, the difference in pro-
liferation between controls and irradiated tumors can be
only minimally affected by limitations in the delivery of
BrdUrd. Those cells were not hypoxic at the time of harvest
(negative for CCI-103F), indicating that, upon improved
oxygen tension, irradiated hypoxic cells can be recruited
back into active proliferation.
Oxygen Delivery Relative to Oxygen Consumption after
Irradiation
The proportions of proliferating cells and hypoxic cells
decreased and the number of apoptotic cells increased with-
in 4 to 8 h after irradiation. Therefore, it is likely that the
initial radiation-induced decrease in hypoxic fraction was
caused by reduced cellular respiration. The nadir of hypoxia
and proliferation was reached in parallel with the maximum
number of apoptotic cells. This might be explained by low
overall cellular respiration due to preferentially radiation-
induced killing of the proliferating cell population (61). At
28 h after treatment, the level of apoptosis and the BrdUrd-
labeling index was almost back to pretreatment levels while
the amount of hypoxia remained low. Since radiation did
not affect the perfused fraction or the vascular density, it
is unlikely that the blood supply in C38 tumors was af-
fected by radiation. The decreased overall cell density may
explain the remaining improvement of the oxygen tension.
In vivo-ex vivo analysis of the hypoxia marker AF2, a 5-
nitrofuran, showing increased diffusion distances after ra-
diation provided evidence that the decrease in tumor cell
hypoxia could be explained by decreased oxygen con-
sumption (28). Our data were also in agreement with math-
ematical modeling indicating that a change in oxygen con-
sumption can be relatively more important that an increase
in oxygen delivery (68).
Clinical Relevance
In human head and neck tumors and xenografts, it has
been shown that heterogeneities in patterns of tumor cell
proliferation and hypoxia are present even in tumors with
similar histo-pathological features (4, 40, 66). In addition,
tumor line-dependent differences in the hypoxic cell turn-
over rate of at least a factor of three were recently dem-
onstrated (37). Temporary improvements in tumor pO2 after
irradiation, ranging from hours to days, have been reported
in different tumor models. Also, the time until a steady-
state level of hypoxia was reached after irradiation differed
between tumor models (26–29, 31, 49). Although they were
not observed in the current study, differences in the effects
of radiation on tumor perfusion have been reported (27, 28,
31, 59). Comparison of different studies may be influenced
by methodological differences, but tumor line-dependent
differences have been reported within the same study (29,
37). From the above-mentioned aspects, it can be conclud-
ed that differences in the response to anticancer treatments
with respect to dynamics of hypoxia, proliferation and/or
apoptosis are likely to exist among patients.
The use of a large single dose of 20 Gy may have its
limitations, although such a dose is equivalent to a full
curative clinical radiotherapy dose. Furthermore, it has been
shown with radiobiological assays that reoxygenation can
be detected after a single dose of 10 Gy (28, 49). The C38
tumor line used in the current study has a high intrinsic cell
loss factor (59%), a high BrdUrd labeling index [24% (flow
cytometry)] (37) and a hypoxic fraction ranging from 13
to 34% (current study). Therefore, this is a hypoxic and
probably radioresistant tumor line, which was the rationale
for the large radiation dose. It is likely that a lower dose
of X rays would affect only the extent of the observed
changes in the tumor microenvironment, but it is unlikely
that this would affect the kinetics of the cellular responses
to irradiation.
After fractionated treatments, improved tumor oxygena-
tion has been measured since the effects of each fraction
are cumulative (69, 70). For quantitative analysis (as per-
formed in this study) of clinically relevant doses (2 Gy),
several fractions would be required. However, between the
delivered fractions, DNA repair and re-oxygenation occur
and affect the subsequent dose, making a fractionated ir-
radiation schedule difficult to interpret for studies of the
kinetics of treatment induced cellular responses.
Conclusion
The oxygenation status of most tumor cells that were
hypoxic at the time of a single dose of radiation (20 Gy)
had improved at 8 h after treatment and remained un-
changed over the subsequent 20 h. After a temporary de-
crease in proliferation and increase in apoptosis, both pa-
rameters had almost returned to pretreatment levels 28 h
after irradiation. The tumor blood perfusion was unaffected
by radiation. These data indicate an increase in tumor ox-
ygenation status after irradiation. The most likely expla-
nation is a decrease in cellular respiration.
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